Key facts
- Ongeno’s last known valuation is $72.6M (Jan 2025).
- It has raised $3.6M; the latest was Later Stage VC ($3.6M) in Jan 2025.
- Notable investors include JRH.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Ongeno
- ·The full record, as it builds
Funding rounds
No funding rounds for Ongeno are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ongeno
Operator of a medical technology intended to treat several autoimmune diseases. The company focuses on the use of stem cells in regenerative medicine and uses autological transfer of bone marrow stem cells, enabling the healthcare industry to treat multiple sclerosis.
- Sector
- Healthcare
- HQ
- Krakow, Poland
- Founded
- 2017
- Employees
- 2
- Website
- ongeno.com/
- Ownership
- Privately Held (backing)
Ongeno doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ongeno shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ongeno in its N-PORT filings yet. We sweep new filings monthly.